基于二代测序的胚胎植入前非整倍体遗传学检测中嵌合体胚胎检出率相关因素及嵌合体胚胎移植妊娠结局分析
回顾性分析745个PGT-A周期2850个囊胚,嵌合体检出率15.6%,滋养外胚层细胞分级B-级及不同遗传检测机构与检出率相关;嵌合体胚胎移植临床妊娠率51.0% vs 整倍体65.2%、活产率39.4% vs 53.2%,均显著降低。
要点
- 2850个囊胚中嵌合体444个(15.6%),片段嵌合245个(55.2%)最常见。
- 滋养外胚层细胞B-级较A级嵌合体检出率升高(OR=1.59,95%CI 1.04~2.44)。
- 嵌合体胚胎移植临床妊娠率和活产率均显著低于整倍体胚胎移植。
核心结论
- 滋养外胚层细胞分级和遗传检测机构与嵌合体胚胎检出率有关。
- 与整倍体胚胎移植相比,嵌合体胚胎移植的临床妊娠率和活产率均明显降低。
- 对于无整倍体胚胎可移植的夫妇,在遗传咨询中可根据嵌合比例和嵌合类型等适当推荐移植嵌合体胚胎,以期获得最优妊娠结局。
研究设计与样本
- 回顾性观察研究,纳入重庆市妇幼保健院生殖医学中心2019年1月至2023年5月745个PGT-A周期共2850个囊胚。
- 使用NGS技术对活检细胞检测,胚胎分为整倍体、非整倍体和嵌合体三组。
- 比较98个嵌合体胚胎移植周期与486个整倍体胚胎移植周期的妊娠结局。
主要发现
- 2850个囊胚中整倍体1489个(52.2%,1489/2850)、非整倍体917个(32.2%,917/2850)、嵌合体444个(15.6%,444/2850)。
- 嵌合体中片段嵌合245个(55.2%,245/444)、整条染色体嵌合118个(26.6%,118/444)、复杂嵌合81个(18.2%,81/444)。
- 4家遗传检测机构的嵌合体检出率波动范围为13.5%~27.0%。
- 多因素分析:滋养外胚层细胞B-级较A级嵌合体检出率升高(OR=1.59,95%CI 1.04~2.44,P=0.033);检测机构c较机构a嵌合体检出率升高(OR=2.89,95%CI 2.10~3.98,P<0.001)。
- 嵌合体胚胎移植较整倍体胚胎移植临床妊娠率降低(51.0% vs 65.2%,P=0.008)、活产率降低(39.4% vs 53.2%,P=0.017);校正年龄、PGT-A指征、滋养外胚层细胞分级和胚胎体外培养天数后,临床妊娠率(OR=0.52,95%CI 0.32~0.83,P=0.007)和活产率(OR=0.50,95%CI 0.31~0.83,P=0.007)仍显著降低。
关键数值与推荐
- 女方年龄、抗苗勒管激素水平、PGT-A指征、促排卵方案、Gn用量、Gn天数、内细胞团分级、滋养外胚层细胞分级、遗传检测机构和胚胎活检时间在三组间分布均有显著差异(P均<0.05)。
临床怎么用
- 作者认为,对于无整倍体胚胎可移植的夫妇,在遗传咨询中可根据嵌合比例和嵌合类型等适当推荐移植嵌合体胚胎,以期获得最优妊娠结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the related factors influencing the detection rate of mosaic embryo and the pregnancy outcomes of mosaic embryo transfer in preimplantation genetic testing for aneuploidy (PGT-A) based on next generation sequencing (NGS) technology. Methods: A retrospective study was performed to analyze the clinical data of patients in 745 PGT-A cycles from January 2019 to May 2023 at Chongqing Health Center for Women and Children, including 2 850 blastocysts. The biopsy cells were tested using NGS technology, and the embryos were divided into three groups based on the test results, namely euploid embryos, aneuploid embryos and mosaic embryos. The influence of population characteristics and laboratory-related parameters on the detection rate of mosaic embryo were analyzed, and the pregnancy outcomes of 98 mosaic embryo transfer cycles and 486 euploid embryo transfer cycles were compared during the same period, including clinical pregnancy rate and live birth rate. Results: Among the embryos tested (n=2 850), the number and proportion of euploid embryos, aneuploid embryos and mosaic embryos were 1 489 (52.2%, 1 489/2 850), 917 (32.2%, 917/2 850) and 444 (15.6%, 444/2 850), respectively. Among mosaic embryos, 245 (55.2%, 245/444) were segmental mosaic embryos, 118 (26.6%, 118/444) were whole-chromosome mosaic embryos, and 81 (18.2%, 81/444) were complex mosaic embryos. NGS technology was performed in 4 genetic testing institutions and the detection rate of mosaic embryo fluctuated from 13.5% to 27.0%. The distributions of female age, level of anti-Müllerian hormone, PGT-A indications, ovulation-inducing treatments, gonadotropin (Gn) dosage, Gn days, inner cell mass grade, trophectoderm cell grade, genetic testing institutions and developmental stage of blastocyst were significantly different among the three groups (all P<0.05). Multi-factor analysis showed that the trophectoderm cell grade and genetic testing institutions were significantly related to the detection rate of mosaic embryo; compared with the trophectoderm cell graded as A, the detection rate of mosaic embryo was significantly increased in the trophectoderm cell graded as B-(OR=1.59, 95%CI: 1.04-2.44, P=0.033); compared with genetic testing institution a, the detection rate of mosaic embryo was significantly higher (OR=2.89, 95%CI: 2.10-3.98, P<0.001) in the testing institution c. The clinical pregnancy rate and live birth rate with mosaic embryos transfer were significantly lower than those of euploid embryos transfer (clinical pregnancy rate: 51.0% vs 65.2%, P=0.008; live birth rate: 39.4% vs 53.2%, P=0.017). After adjustment for age, PGT-A indications, trophectoderm cell grade and days of embryo culture in vitro, the clinical pregnancy rate and live birth rate with mosaic embryos transfer were significantly lower than those of euploid embryos transfer (clinical pregnancy rate: OR=0.52, 95%CI: 0.32-0.83, P=0.007; live birth rate: OR=0.50, 95%CI: 0.31-0.83, P=0.007). Conclusions: The trophectoderm cell grade and genetic testing institutions are related to the detection rate of mosaic embryo. Compared with euploid embryos transfer, the clinical pregnancy rate and live birth rate with mosaic embryos transfer are significantly reduced. For infertile couple without euploid embryos, transplantable mosaic embryos could be recommended according to the mosaic ratio and mosaic type in genetic counseling to obtain the optimal pregnancy outcome. 目的: 分析基于二代测序(NGS)技术的胚胎植入前非整倍体遗传学检测(PGT-A)中嵌合体胚胎检出率的相关因素,以及嵌合体胚胎移植的妊娠结局。 方法: 通过回顾性观察研究收集重庆市妇幼保健院生殖医学中心2019年1月至2023年5月期间的745个PGT-A周期2 850个囊胚患者的临床资料。使用NGS技术对活检细胞进行检测,根据检测结果将胚胎分为整倍体胚胎、非整倍体胚胎及嵌合体胚胎,比较患者的临床特征及实验室相关参数对嵌合体胚胎检出率的影响。分析比较同期98个嵌合体胚胎移植周期和486个整倍体胚胎移植周期的妊娠结局,包括临床妊娠率和活产率。 结果: 在2 850个囊胚中,1 489个囊胚为整倍体(52.2%,1 489/2 850),917个(32.2%,917/2 850)为非整倍体,444个(15.6%,444/2 850)为嵌合体;嵌合体中,有245个(55.2%,245/444)胚胎为染色体片段嵌合,118个(26.6%,118/444)为整条染色体嵌合,81个(18.2%,81/444)为复杂嵌合。不同遗传检测机构的嵌合体检出率波动范围为13.5%~27.0%。女方年龄、抗苗勒管激素水平、PGT-A指征、促排卵方案、促性腺激素(Gn)用量、Gn天数、内细胞团分级、滋养外胚层细胞分级、遗传检测机构和胚胎活检时间在整倍体、非整倍体和嵌合体胚胎间分布均有显著差异(P均<0.05)。多因素分析显示,滋养外胚层细胞分级和遗传检测机构与嵌合体检出率明显相关,与滋养外胚层细胞分级为A级相比,分级为B-级者(OR=1.59,95%CI为1.04~2.44,P=0.033)嵌合体检出率明显升高;与检测机构a相比,c机构的嵌合体检出率明显升高(OR=2.89,95%CI为2.10~3.98,P<0.001)。嵌合体胚胎移植的临床妊娠率(分别为51.0%、65.2%,P=0.008)和活产率(分别为39.4%、53.2%,P=0.017)明显低于整倍体胚胎移植者;在校正了女方年龄、PGT-A指征、滋养外胚层细胞分级和胚胎体外培养天数后,嵌合体胚胎移植者的临床妊娠率(OR=0.52,95%CI为0.32~0.83,P=0.007)和活产率(OR=0.50,95%CI为0.31~0.83,P=0.007)均明显低于整倍体胚胎移植者。 结论: 滋养外胚层细胞分级和遗传检测机构与嵌合体胚胎检出率有关。与整倍体胚胎移植相比,嵌合体胚胎移植的临床妊娠率和活产率均明显降低。对于无整倍体胚胎可移植的夫妇,在遗传咨询中可根据嵌合比例和嵌合类型等适当推荐移植嵌合体胚胎,以期获得最优妊娠结局。.
引用
- Zhang Q, Xiong S, Han W, et al. [Analysis of related factors influencing the detection rate of mosaic embryo and the pregnancy outcomes with mosaic embryo transfers]. Zhonghua Fu Chan Ke Za Zhi. 2024. PMID: 38644275. doi:10.3760/cma.j.cn112141-20240104-00010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。